Voyager Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $6,278 | $24,629 | $29,578 | $19,516 |
Gross Profit | 6,278 | 24,629 | -4,874 | 18,320 |
EBITDA | -37,288 | -12,648 | -13,633 | -14,987 |
EBIT | -38,299 | -13,780 | -15,025 | -16,183 |
Net Income | -34,487 | -9,044 | -10,141 | -11,330 |
Net Change In Cash | 6,278 | 24,629 | 29,578 | 19,516 |
Free Cash Flow | -14,684 | -28,226 | -32,547 | 56,626 |
Cash | 71,367 | 112,525 | 76,127 | 143,078 |
Basic Shares | 57,667 | 57,851 | 57,721 | 57,117 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $80,001 | $250,008 | $40,907 | $37,415 |
Gross Profit | 80,001 | 245,567 | 40,907 | 37,415 |
EBITDA | -83,287 | 126,455 | -44,646 | -68,453 |
EBIT | 122,014 | -50,837 | -73,618 | |
Net Income | -65,002 | 132,330 | -46,408 | -66,032 |
Net Change In Cash | 80,001 | 250,008 | 40,907 | 37,415 |
Cost of Revenue | -18,738 | 12,993 | ||
Free Cash Flow | -18,831 | 74,663 | -15,000 | -55,134 |
Cash | 71,367 | 68,802 | 98,959 | 117,433 |
Basic Shares | 57,667 | 44,569 | 38,356 | 37,668 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.59 |
2024-09-30 | -$0.16 |
2024-06-30 | -$0.18 |
2024-03-31 | -$0.20 |
